Opinion|Videos|February 9, 2026
Barriers to Managing Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs help overcome social and systemic barriers to Alzheimer care.
Advertisement
Episodes in this series
Panelists discuss how social, financial, and systemic challenges hinder Alzheimer management. Limited access to specialists, diagnostic costs, and caregiver burnout are recurring themes.
Panelists discuss how APPs advocate for patients by navigating insurance processes, connecting families with resources, and promoting equitable access to care regardless of socioeconomic status.
Panelists discuss how addressing these barriers requires policy awareness and community outreach. APPs’ holistic approach positions them as champions of accessible, patient-centered care.
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5